Nutriband Inc. Reports 51% Revenue Growth and Strong Cash Position to Advance AVERSA Fentanyl Program
TL;DR
Nutriband's AVERSA Fentanyl could capture a first-mover advantage with estimated peak annual sales up to $200 million if approved.
Nutriband's NDA for AVERSA Fentanyl relies solely on Phase 1 data with no Phase 2 or 3 trials required for FDA approval.
AVERSA technology prevents abuse of potent drugs, making transdermal patches safer for patients and reducing diversion risks in communities.
Nutriband's revenue grew over 50% year-over-year while developing the world's first abuse-deterrent fentanyl patch using innovative AVERSA technology.
Found this article helpful?
Share it with your network and spread the knowledge!
Nutriband Inc. (NASDAQ: NTRB) reported financial results for the six months ended July 31, 2025, demonstrating substantial growth with revenue reaching $1.29 million, representing a 50.87% increase compared to the same period last year. The company maintains a strong cash position of $6.9 million, providing financial stability to support the advancement of its lead product candidate, AVERSA™ Fentanyl.
The company has scheduled a Type C FDA meeting for September 18 to discuss the regulatory pathway for AVERSA Fentanyl. Notably, the New Drug Application (NDA) for this product will rely solely on data from a single Phase 1 Human Abuse Potential study, eliminating the need for Phase 2 or Phase 3 clinical trials. This streamlined regulatory approach could significantly accelerate the product's path to market approval.
If approved, AVERSA Fentanyl would become the first and only abuse-deterrent transdermal fentanyl product available globally. Market projections indicate peak annual sales potential between $80 million and $200 million, representing a substantial commercial opportunity in the pain management sector. The company's second development program, AVERSA Buprenorphine, is projected to achieve peak annual sales of up to $130 million.
Nutriband's revenue growth has been supported by its contract manufacturing subsidiary, Pocono Pharma, which contributed to the record performance during the first half of the fiscal year. The company's AVERSA™ technology platform is designed to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential, and can be incorporated into any transdermal patch formulation.
The development of abuse-deterrent formulations addresses a critical public health need, particularly in the context of the ongoing opioid crisis. Successful commercialization of AVERSA Fentanyl could provide healthcare providers with additional tools to manage pain while reducing the risk of opioid abuse and diversion. Additional information about the company's development programs and technology platform is available at https://www.nutriband.com.
Curated from InvestorBrandNetwork (IBN)
